Evaluation of the clinical performance of OncoPredict HPV® SCR assay within the VALGENT‐2 framework
Journal of Medical Virology · 2023
DOI: 10.1002/jmv.28417 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, 2023. Verfasst von Sharonjit K Dhillon und 8 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Cancer Epidemiology/Belgian Cancer Centre, Scientific Institute of Public Health, Brussels, Belgium. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Papillomavirus Infections, Uterine Cervical Dysplasia. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: European Commission.
Abstract (Originalsprache)
Human papillomavirus (HPV) assays used in cervical cancer screening should be clinically validated according to international criteria. OncoPredict HPV® Screening (SCR) is a partial genotyping multiplex real‐time PCR assay targeting E6/E7 genes of 13 high‐risk (hr) HPVs. OncoPredict HPV® SCR (index assay) identifies HPV‐16 and HPV‐18 separately, 11 other hrHPV in aggregate and includes quality controls for sample adequacy, DNA extraction efficiency and PCR inhibition. 1300 VALGENT‐2 study samples (from women aged 20–60 attending the Scottish cervical cancer screening program) were tested with the index assay and the GP5+/6+ PCR enzyme immunoassay (standard comparator assay). Non‐inferior accuracy detecting cervical intraepithelial neoplasia of grade 2 or worse (CIN2+) of the index versus comparator was verified. Intra‐ and interlaboratory reproducibility of the index was evaluated by overall concordance and Cohen's kappa, using a sub‐population ( n = 526). Relative sensitivity and specificity for CIN2+ of the index versus comparator were 1.01 (95% confidence interval [CI]: 0.99–1.03) and 1.02 (95% CI: 1.0–1.04), respectively. Noninferiority p values were all ≤0.05, except for CIN3+ in patients ≥30 years. Excellent intra‐ and interlaboratory reproducibility was shown with concordance >98% and kappas >0.95. OncoPredict HPV® SCR fulfills the three international validation criteria for hrHPV DNA tests in cervical cancer screening.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Unit of Cancer Epidemiology/Belgian Cancer Centre, Scientific Institute of Public Health, Brussels, Belgium.
- Laboratory of Clinical Microbiology and Virology, Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
- Scottish HPV Reference Laboratory, Royal Infirmary of Edinburgh, Edinburgh, Scotland, UK.
- HPV Research Group, Centre for Reproductive Health, University of Edinburgh, Edinburgh, Scotland, UK.
- Department of Human Structure and Repair, Faculty of Medicine and Health Sciences, University Ghent, Ghent, Belgium.
ORCID-Profile: Clementina E Cocuzza, Ramya Bhatia
Förderung
- European Commission
Zitieren
APA
Dhillon, S. K., Cocuzza, C. E., Chung, P. Y. J., Martinelli, M., Giubbi, C., Njoku, R. C., Bhatia, R., Cuschieri, K., & Arbyn, M. (2023). Evaluation of the clinical performance of OncoPredict HPV® SCR assay within the VALGENT‐2 framework. Journal of Medical Virology. https://doi.org/10.1002/jmv.28417
Vancouver
Dhillon SK, Cocuzza CE, Chung PYJ, Martinelli M, Giubbi C, Njoku RC, et al. Evaluation of the clinical performance of OncoPredict HPV® SCR assay within the VALGENT‐2 framework. Journal of Medical Virology. 2023. doi:10.1002/jmv.28417
BibTeX
@article{Dhillon2023,
author = {Dhillon, Sharonjit K and Cocuzza, Clementina E and Chung, Pui Yan Jenny and Martinelli, Marianna and Giubbi, Chiara and Njoku, Ruth C and Bhatia, Ramya and Cuschieri, Kate and Arbyn, Marc},
title = {Evaluation of the clinical performance of OncoPredict HPV® SCR assay within the VALGENT‐2 framework},
journal = {Journal of Medical Virology},
year = {2023},
doi = {10.1002/jmv.28417}
}
EUVIMED